Acute Myeloid Leukemia Market Outlook (2026–2030): Long-Term Insights

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Acute Myeloid Leukemia Market During 2026–2030?

The acute myeloid leukemia market has experienced robust growth in recent years. It is projected to increase from $3.73 billion in 2025 to $3.97 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.3%. This historical market expansion was driven by factors such as the rising prevalence of AML, improvements in hospital infrastructure, heightened awareness about leukemia treatments, the continued use of conventional chemotherapy protocols, and the evolution of supportive care measures.

The acute myeloid leukemia market is projected for significant expansion in the coming years. It is anticipated to reach $5.25 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.3%. This growth over the forecast period is propelled by advancements in targeted therapy drugs, a rise in stem cell transplant procedures, the creation of new tyrosine kinase inhibitors, the expansion of ambulatory care centers, and the adoption of personalized medicine strategies in treatment. Key trends expected during this period involve the increasing uptake of targeted AML therapies, a greater reliance on stem cell transplantation procedures, an escalating need for personalized chemotherapy regimens, the expansion of tyrosine kinase inhibitors and monoclonal antibodies, and a heightened emphasis on early diagnosis and AML monitoring.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/acute-myeloid-leukemia-global-market-report

What Key Factors Are Shaping The Acute Myeloid Leukemia Market Landscape?

The increasing integration of personalized medicine is expected to propel the growth of the acute myeloid leukemia market going forward. Personalized medicine represents an advanced approach to healthcare and medical treatment that considers individual patients’ specific genes, environments, and lifestyles. For acute myeloid leukemia (AML), this involves utilizing molecular profiling to identify distinct genetic mutations and biomarkers unique to each patient. This data then guides the selection of targeted therapies and customized treatment plans, thereby optimizing the effectiveness of interventions and minimizing adverse effects, leading to a more individualized and precise method for AML management. For instance, in February 2024, the Personalised Medicine Coalition, a US-based hospital and health care organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, an increase from six in 2022. Therefore, the expanding adoption of personalized medicine is driving the growth of the acute myeloid leukemia market.

What Are The Key Segment Divisions In The Acute Myeloid Leukemia Market Segment Structure?

The acute myeloid leukemia market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Stem Cell Transplant, Targeted Therapy

2) By Treatment Phase: Induction Therapy, Consolidation Therapy, Maintenance Therapy, Relapsed Or Refractory Therapy

3) By End-User: Hospitals, Specialty Oncology Centers, Transplant Centers, Research and Academic Institutes

Subsegments:

1) By Chemotherapy: Cytarabine-Based Therapy, Anthracycline-Based Therapy, Hypomethylating Agents, Low-Intensity Chemotherapy, Combination Chemotherapy Regimens

2) By Stem Cell Transplant: Allogeneic Stem Cell Transplant, Autologous Stem Cell Transplant, Conditioning Regimens, Post-Transplant Maintenance Therapy

3) By Targeted Therapy: FLT3 Inhibitors, IDH1 Inhibitors, IDH2 Inhibitors, BCL-2 Inhibitors, Hedgehog Pathway Inhibitors, Monoclonal Antibodies, Other Targeted Agents

What Market Trends Are Affecting The Acute Myeloid Leukemia Market?

Major companies operating in the acute myeloid leukemia market are dedicated to developing advanced drug solutions, including maintenance monotherapy, to broaden their product portfolios with the goal of improving patient outcomes and addressing unmet medical needs. Maintenance monotherapy refers to a medical treatment approach where a single therapeutic agent is given to a patient as an ongoing, long-term therapy to prevent the recurrence or progression of a medical condition. For example, in July 2023, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical firm, received United States Food and Drug Administration (USFDA) approval for quizartinib (Vanflyta). This approval covers its use in combination with standard cytarabine and anthracycline induction, followed by cytarabine consolidation, and as maintenance monotherapy for treating newly diagnosed acute myeloid leukemia (AML) in adults with FLT3 internal tandem duplication (ITD)-positive status, as confirmed by an FDA-approved test. The LeukoStrat CDx FLT3 Mutation Assay has also been approved as a companion diagnostic for Vanflyta. This approval is founded on positive results from the QuANTUM-First trial, which showed a statistically significant improvement in overall survival for patients receiving quizartinib compared to a placebo. Quizartinib’s recommended dosage varies across the induction, consolidation, and maintenance phases. It is important to note that the drug is not indicated as maintenance monotherapy after allogeneic hematopoietic stem cell transplantation.

Which Organizations Are Engaged In The Acute Myeloid Leukemia Market?

Major companies operating in the acute myeloid leukemia market are Pfizer Inc., AbbVie Inc., Novartis AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche AG, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Servier Pharmaceuticals, Amgen Inc., Otsuka Holdings Co. Ltd., Agios Pharmaceuticals Inc., Syndax Pharmaceuticals Inc., MEI Pharma Inc., SELLAS Life Sciences Group, Genmab AS, Aptose Biosciences Inc., Daiichi Sankyo Company Limited, BeiGene Ltd., Jazz Pharmaceuticals plc, Ipsen S.A.

Get The Full Acute Myeloid Leukemia Market Report:

https://www.thebusinessresearchcompany.com/report/acute-myeloid-leukemia-global-market-report

Which Region Leads The Acute Myeloid Leukemia Market In Overall Market Size?

North America was the largest region in the acute myeloid leukemia market in 2025. The regions covered in the acute myeloid leukemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Acute Myeloid Leukemia Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/acute-myeloid-leukemia-global-market-report

Browse Through More Reports Similar to the Global Acute Myeloid Leukemia Market 2026, By The Business Research Company

Chronic Myeloid Leukemia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-myeloid-leukemia-treatment-global-market-report

Chronic Myeloid Leukemia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-myeloid-leukemia-treatment-global-market-report

Leqembi Market Report 2026

https://www.thebusinessresearchcompany.com/report/leqembi-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795